EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

A Phenomap of TTR Amyloidosis to Aid Diagnostic Screening

Alexios S Antonopoulos, Theodoros Tsampras, George Lazaros, Konstantinos Tsioufis, Charalambos Vlachopoulos

ESC Heart Failure · 01.04.2025 · 12 (2) · 1113-1118

DOI: 10.1002/ehf2.15143 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ESC Heart Failure, online erschienen am 31.10.2024. Verfasst von Alexios S Antonopoulos und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cardiogenetics Unit, 1st Cardiology Department, Hippokration Hospital, National and Kapodistrian University of Athens, Athens, Greece. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Prealbumin, Cardiomyopathies, Mutation. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiac amyloidosis due to transthyretin (ATTR) remains an underdiagnosed cause of cardiomyopathy. As awareness of the disease grows and referrals for ATTR increase, clinicians are likely to encounter more atypical forms of the condition in clinical practice. Therefore, physicians and treating cardiologists should be aware of the full phenotypic spectrum of ATTR. The phenotypic manifestation of ATTR varies depending on the stage of the disease, the presence and type of TTR mutation and the patient's comorbidities. ATTR findings can be grouped into four major categories: clinical profile and cardiac phenotype, extra-cardiac findings, electrocardiogram and imaging findings, which cumulatively form the full phenomap of ATTR. Results from any diagnostic test for ATTR should be interpreted in light of the pre-test probability for the disease. Findings that suggest negative markers for ATTR can point towards other forms of amyloidosis (such as AL amyloidosis) or alternate causes of left ventricular hypertrophy, including hypertrophic cardiomyopathy or Fabry disease. The rising number of referrals for ATTR cardiomyopathy presents a challenge in daily clinical practice. To prevent an increase in false-positive diagnostic test results, an ATTR phenomap can serve as a valuable tool for guiding diagnostic assessments, interpreting test outcomes and prioritizing appropriate referrals for ATTR screening.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid Neuropathies, FamilialPrealbuminCardiomyopathiesMutationMass ScreeningHumansPhenotypeElectrocardiography

Stichwörter der Autor:innen

AL amyloidosiscardiac amyloidosisheart failurepreserved ejection fractiontransthyretin amyloidosis

Substanzen

Prealbumin

Autor:innen und Institutionen

  • Cardiogenetics Unit, 1st Cardiology Department, Hippokration Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Zitieren

APA

Antonopoulos, A. S., Tsampras, T., Lazaros, G., Tsioufis, K., & Vlachopoulos, C. (2025). A Phenomap of TTR Amyloidosis to Aid Diagnostic Screening. ESC Heart Failure, 12(2), 1113-1118. https://doi.org/10.1002/ehf2.15143

Vancouver

Antonopoulos AS, Tsampras T, Lazaros G, Tsioufis K, Vlachopoulos C. A Phenomap of TTR Amyloidosis to Aid Diagnostic Screening. ESC Heart Failure. 2025;12(2):1113-1118. doi:10.1002/ehf2.15143

BibTeX
@article{Antonopoulos2025,
  author = {Antonopoulos, Alexios S and Tsampras, Theodoros and Lazaros, George and Tsioufis, Konstantinos and Vlachopoulos, Charalambos},
  title = {A Phenomap of TTR Amyloidosis to Aid Diagnostic Screening},
  journal = {ESC Heart Failure},
  year = {2025},
  volume = {12},
  number = {2},
  pages = {1113--1118},
  doi = {10.1002/ehf2.15143}
}
Kostenlos starten →